Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Influenza

  Free Subscription


Articles published in Antiviral Res

Retrieve available abstracts of 75 articles:
HTML format
Text format



Single Articles


    July 2019
  1. ABED Y, Fage C, Checkmahomed L, Begin G, et al
    The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.
    Antiviral Res. 2019 Jul 16:104561. doi: 10.1016/j.antiviral.2019.104561.
    PubMed     Text format     Abstract available


  2. SEDEYN K, Saelens X
    New antibody-based prevention and treatment options for influenza.
    Antiviral Res. 2019 Jul 16:104562. doi: 10.1016/j.antiviral.2019.104562.
    PubMed     Text format     Abstract available


    June 2019
  3. MIFSUD EJ, Hayden FG, Hurt AC
    Antivirals targeting the polymerase complex of influenza viruses.
    Antiviral Res. 2019 Jun 24:104545. doi: 10.1016/j.antiviral.2019.104545.
    PubMed     Text format     Abstract available


  4. MCKIMM-BRESCHKIN JL, Barrett S, McKenzie-Kludas C, McAuley J, et al
    Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant.
    Antiviral Res. 2019;169:104542.
    PubMed     Text format     Abstract available


  5. ADAMS SE, Lee N, Lugovtsev VY, Kan A, et al
    Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.
    Antiviral Res. 2019;169:104539.
    PubMed     Text format     Abstract available


  6. ARTARINI A, Meyer M, Shin YJ, Huber K, et al
    Regulation of influenza a virus mRNA splicing by CLK1.
    Antiviral Res. 2019 Jun 6. pii: S0166-3542(18)30668.
    PubMed     Text format     Abstract available


    May 2019
  7. FARRUKEE R, Butler J, Reading PC, Hurt AC, et al
    Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Antiviral Res. 2019 May 24. pii: S0166-3542(18)30673.
    PubMed     Text format     Abstract available


  8. GEORGEL AF, Cayet D, Pizzorno A, Rosa-Calatrava M, et al
    Toll-like receptor 5 agonist flagellin reduces Influenza A Virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir.
    Antiviral Res. 2019 May 9. pii: S0166-3542(18)30570.
    PubMed     Text format     Abstract available


  9. KOTOMINA T, Isakova-Sivak I, Matyushenko V, Kim KH, et al
    Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.
    Antiviral Res. 2019 May 7. pii: S0166-3542(19)30121.
    PubMed     Text format     Abstract available


    April 2019
  10. CHIBANGA VP, Dirr L, Guillon P, El-Deeb IM, et al
    New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase.
    Antiviral Res. 2019 Apr 2. pii: S0166-3542(18)30740.
    PubMed     Text format     Abstract available


  11. TARASOV SA, Zarubaev VV, Gorbunov EA, Sergeeva SA, et al
    Retraction notice to "Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice" [Antiviral Research 93 (2012) 219-224].
    Antiviral Res. 2019;164:177.
    PubMed     Text format    


    March 2019
  12. NANNETTI G, Massari S, Mercorelli B, Bertagnin C, et al
    Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance.
    Antiviral Res. 2019 Mar 15. pii: S0166-3542(18)30659.
    PubMed     Text format     Abstract available


    February 2019
  13. KOSZALKA P, Tilmanis D, Roe M, Vijaykrishna D, et al
    Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
    Antiviral Res. 2019 Feb 13. pii: S0166-3542(18)30698.
    PubMed     Text format     Abstract available


  14. MOHL G, Liddle N, Nygaard J, Dorius A, et al
    Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5.
    Antiviral Res. 2019 Feb 8. pii: S0166-3542(18)30487.
    PubMed     Text format     Abstract available


  15. HONG JY, Chen TH, Chen YJ, Liu CC, et al
    Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development.
    Antiviral Res. 2019;164:12-22.
    PubMed     Text format     Abstract available


    January 2019
  16. WATANABE A, Ishida T, Hirotsu N, Kawaguchi K, et al
    Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
    Antiviral Res. 2019;163:75-81.
    PubMed     Text format     Abstract available


  17. KIM MH, Kang JO, Kim JY, Jung HE, et al
    Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus.
    Antiviral Res. 2019 Jan 9. pii: S0166-3542(18)30589.
    PubMed     Text format     Abstract available


    December 2018
  18. GARG R, Latimer L, Gomis S, Gerdts V, et al
    Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Antiviral Res. 2018 Dec 11. pii: S0166-3542(18)30464.
    PubMed     Text format     Abstract available


    October 2018
  19. SONG L, Xiong D, Kang X, Jiao Y, et al
    The optimized fusion protein HA1-2-FliC big up tri, openD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
    Antiviral Res. 2018 Oct 30. pii: S0166-3542(18)30186.
    PubMed     Text format     Abstract available


  20. NOSHI T, Kitano M, Taniguchi K, Yamamoto A, et al
    In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
    Antiviral Res. 2018 Oct 11. pii: S0166-3542(18)30363.
    PubMed     Text format     Abstract available


  21. PICHON M, Picard C, Simon B, Gaymard A, et al
    Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.
    Antiviral Res. 2018;160:1-9.
    PubMed     Text format     Abstract available


    September 2018
  22. ABED Y, Tu V, Carbonneau J, Checkmahomed L, et al
    Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
    Antiviral Res. 2018 Sep 13. pii: S0166-3542(18)30313.
    PubMed     Text format     Abstract available


  23. KOLPE A, Schepens B, Ye L, Staeheli P, et al
    Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.
    Antiviral Res. 2018 Sep 1. pii: S0166-3542(18)30314.
    PubMed     Text format     Abstract available


    August 2018
  24. XIA C, Seo YJ, Studstill CJ, Vijayan M, et al
    Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice.
    Antiviral Res. 2018 Aug 17. pii: S0166-3542(18)30220.
    PubMed     Text format     Abstract available


  25. SOOD R, Kumar N, Bhatia S, Chanu KV, et al
    Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
    Antiviral Res. 2018 Aug 17. pii: S0166-3542(18)30167.
    PubMed     Text format     Abstract available


  26. BRODSKAIA AV, Timin AS, Gorshkov AN, Muslimov AR, et al
    Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers.
    Antiviral Res. 2018 Aug 6. pii: S0166-3542(17)30732.
    PubMed     Text format     Abstract available


    July 2018
  27. GARG R, Brownlie R, Latimer L, Gerdts V, et al
    A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Antiviral Res. 2018;158:78-87.
    PubMed     Text format     Abstract available


  28. SCHRADER T, Dudek SE, Schreiber A, Ehrhardt C, et al
    The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.
    Antiviral Res. 2018 Jul 7. pii: S0166-3542(18)30364.
    PubMed     Text format     Abstract available


  29. LACKENBY A, Besselaar TG, Daniels RS, Fry A, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
    Antiviral Res. 2018;157:38-46.
    PubMed     Text format     Abstract available


    June 2018
  30. LA FRAZIA S, Piacentini S, Riccio A, Rossignol JF, et al
    The second-generation thiazolide haloxanide is a potent inhibitor of avian influenza virus replication.
    Antiviral Res. 2018 Jun 13. pii: S0166-3542(18)30079.
    PubMed     Text format     Abstract available


  31. KO EJ, Lee Y, Lee YT, Kim YJ, et al
    MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.
    Antiviral Res. 2018 Jun 6. pii: S0166-3542(18)30007.
    PubMed     Text format     Abstract available


    March 2018
  32. MATOS AR, Resende PC, Miranda MD, Garcia CC, et al
    Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
    Antiviral Res. 2018 Mar 27. pii: S0166-3542(17)30768.
    PubMed     Text format     Abstract available


  33. MCKIMM-BRESCHKIN JL, Barrett S, Wong FYK, Pudjiatmoko, et al
    Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
    Antiviral Res. 2018;153:95-100.
    PubMed     Text format     Abstract available


  34. MALCOLM BA, Aerts CA, Dubois KJ, Geurts FJ, et al
    PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials.
    Antiviral Res. 2018;153:70-77.
    PubMed     Text format     Abstract available


  35. MUSHARRAFIEH R, Ma C, Wang J
    Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.
    Antiviral Res. 2018 Mar 5. pii: S0166-3542(18)30065.
    PubMed     Text format     Abstract available


  36. GU H, Gao Y, Zhou S, Sun F, et al
    Bivalent vaccine platform based on ca influenza virus vaccine elicits protective immunity against human adenoviruses.
    Antiviral Res. 2018 Mar 1. pii: S0166-3542(17)30305.
    PubMed     Text format     Abstract available


    January 2018
  37. HUI DS, Lee N, Chan PK, Beigel JH, et al
    The role of adjuvant immunomodulatory agents for treatment of severe influenza.
    Antiviral Res. 2018;150:202-216.
    PubMed     Text format     Abstract available


    October 2017
  38. MARATHE BM, Mostafa HH, Vogel P, Pascua PNQ, et al
    A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.
    Antiviral Res. 2017 Oct 31. pii: S0166-3542(17)30491.
    PubMed     Text format     Abstract available


  39. SARVESTANI ST, McAuley JL
    The role of the NLRP3 inflammasome in regulation of antiviral responses to influenza A virus infection.
    Antiviral Res. 2017 Oct 30. pii: S0166-3542(17)30611.
    PubMed     Text format     Abstract available


  40. KIM MC, Lee YN, Kim YJ, Choi HJ, et al
    Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
    Antiviral Res. 2017;148:43-52.
    PubMed     Text format     Abstract available


  41. GORDON NA, McGuire KL, Wallentine SK, Mohl GA, et al
    Divalent copper complexes as influenza A M2 inhibitors.
    Antiviral Res. 2017;147:100-106.
    PubMed     Text format     Abstract available


  42. TILMANIS D, van Baalen C, Oh DY, Rossignol JF, et al
    The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
    Antiviral Res. 2017 Oct 3. pii: S0166-3542(17)30546.
    PubMed     Text format     Abstract available


    September 2017
  43. WU Y, Yang D, Xu B, Liang W, et al
    Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.
    Antiviral Res. 2017 Sep 20. pii: S0166-3542(17)30180.
    PubMed     Text format     Abstract available


    August 2017
  44. GUBAREVA LV, Besselaar TG, Daniels RS, Fry A, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Antiviral Res. 2017 Aug 9. pii: S0166-3542(17)30267.
    PubMed     Text format     Abstract available


  45. PICHON M, Gaymard A, Josset L, Valette M, et al
    Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
    Antiviral Res. 2017 Aug 2. pii: S0166-3542(17)30431.
    PubMed     Text format     Abstract available


  46. HU Y, Zhang J, Musharrafieh RG, Ma C, et al
    Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.
    Antiviral Res. 2017;145:103-113.
    PubMed     Text format     Abstract available


  47. ZHANG S, Sun F, Ren T, Duan Y, et al
    Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice.
    Antiviral Res. 2017 Aug 1. pii: S0166-3542(16)30742.
    PubMed     Text format     Abstract available


    June 2017
  48. PAUL SS, Mok CK, Mak TM, Ng OW, et al
    A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin.
    Antiviral Res. 2017 Jun 17. pii: S0166-3542(17)30042.
    PubMed     Text format     Abstract available


  49. LIU M, Lo EC, Wang G, Chow HF, et al
    Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening.
    Antiviral Res. 2017 Jun 16. pii: S0166-3542(16)30584.
    PubMed     Text format     Abstract available


  50. PETROVA NV, Emelyanova AG, Gorbunov EA, Edwards MR, et al
    Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results.
    Antiviral Res. 2017;142:185-192.
    PubMed     Text format     Abstract available


    May 2017
  51. GIAROLA-SILVA S, Coelho-Dos-Reis JGA, Mourao MM, Campi-Azevedo AC, et al
    Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine.
    Antiviral Res. 2017;144:70-82.
    PubMed     Text format     Abstract available


  52. LEE N, Wong CK, Chan MCW, Yeung ESL, et al
    Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial.
    Antiviral Res. 2017 May 20. pii: S0166-3542(17)30141.
    PubMed     Text format     Abstract available


  53. COURTIN N, Fotso AF, Fautrad P, Mas F, et al
    Antiviral activity of formyl peptide receptor 2 antagonists against influenza viruses.
    Antiviral Res. 2017;143:252-261.
    PubMed     Text format     Abstract available


    April 2017
  54. LIU JX, Zhang Y, Hu QP, Li JQ, et al
    Anti-inflammatory effects of rosmarinic acid-4-O-beta-D-glucoside in reducing acute lung injury in mice infected with influenza virus.
    Antiviral Res. 2017 Apr 28. pii: S0166-3542(16)30454.
    PubMed     Text format     Abstract available


  55. WANG M, Wang S, Wang W, Wang Y, et al
    Inhibition effects of novel polyketide compound PPQ-B against influenza A virus replication by interfering with the cellular EGFR pathway.
    Antiviral Res. 2017;143:74-84.
    PubMed     Text format     Abstract available


  56. WANG Y, Wu J, Xue C, Wu Z, et al
    A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Antiviral Res. 2017 Apr 10. pii: S0166-3542(16)30791.
    PubMed     Text format     Abstract available


  57. HAASBACH E, Muller C, Ehrhardt C, Schreiber A, et al
    The MEK-inhibitor CI-1040 displays a broad anti-influenza activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.
    Antiviral Res. 2017 Apr 1. pii: S0166-3542(17)30060.
    PubMed     Text format     Abstract available


  58. YANG JR, Cheng CY, Chen CY, Lin CH, et al
    A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Antiviral Res. 2017;140:62-75.
    PubMed     Text format     Abstract available


  59. ALBULESCU L, Bigay J, Biswas B, Weber-Boyvat M, et al
    Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307.
    Antiviral Res. 2017;140:37-44.
    PubMed     Text format     Abstract available


    March 2017
  60. LEYVA-GRADO VH, Palese P
    Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
    Antiviral Res. 2017;142:12-15.
    PubMed     Text format     Abstract available


    February 2017
  61. PENDZIALEK J, Roose K, Smet A, Schepens B, et al
    Bispecific T-Cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.
    Antiviral Res. 2017 Feb 28. pii: S0166-3542(16)30618.
    PubMed     Text format     Abstract available


  62. GAO L, Han J, Si J, Wang J, et al
    Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro.
    Antiviral Res. 2017 Feb 20. pii: S0166-3542(16)30540.
    PubMed     Text format     Abstract available


  63. COLEMAN BL, Hassan K, Green K, Gubbay JB, et al
    Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05-2013/14, Toronto, Canada.
    Antiviral Res. 2017 Feb 5. pii: S0166-3542(16)30612.
    PubMed     Text format     Abstract available


  64. TAO W, Hurst B, Shakya AK, Uddin MJ, et al
    Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Antiviral Res. 2017 Feb 1. pii: S0166-3542(16)30409.
    PubMed     Text format     Abstract available


    January 2017
  65. HU Y, Musharrafieh R, Ma C, Zhang J, et al
    An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
    Antiviral Res. 2017 Jan 10. pii: S0166-3542(16)30522.
    PubMed     Text format     Abstract available


  66. TELCIAN AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, et al
    Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro.
    Antiviral Res. 2017;137:93-101.
    PubMed     Text format     Abstract available


    December 2016
  67. KOBAYASHI M, Kodama M, Noshi T, Yoshida R, et al
    Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Antiviral Res. 2016 Dec 21. pii: S0166-3542(16)30327.
    PubMed     Text format     Abstract available


    November 2016
  68. YANG WT, Yang GL, Wang Q, Huang HB, et al
    Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
    Antiviral Res. 2016 Nov 28. pii: S0166-3542(16)30462.
    PubMed     Text format     Abstract available


  69. YUAN S, Chu H, Ye J, Singh K, et al
    Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface.
    Antiviral Res. 2016 Nov 10. pii: S0166-3542(16)30372.
    PubMed     Text format     Abstract available


  70. TU V, Abed Y, Barbeau X, Carbonneau J, et al
    The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
    Antiviral Res. 2016;137:6-13.
    PubMed     Text format     Abstract available


    October 2016
  71. SMEE DF, Barnard DL, Jones SM
    Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
    Antiviral Res. 2016 Oct 19. pii: S0166-3542(16)30404.
    PubMed     Text format     Abstract available


  72. WILSON JR, Guo Z, Reber A, Kamal RP, et al
    An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
    Antiviral Res. 2016 Oct 3. pii: S0166-3542(16)30341.
    PubMed     Text format     Abstract available


    February 2016
  73. SODERHOLM S, Anastasina M, Islam MM, Tynell J, et al
    Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.
    Antiviral Res. 2016;126:69-80.
    PubMed     Text format     Abstract available


  74. LYTRAS T, Kossyvakis A, Mentis A
    NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.
    Antiviral Res. 2016;126:18-20.
    PubMed     Text format     Abstract available


  75. YANG JR, Chen CY, Kuo CY, Cheng CY, et al
    A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
    Antiviral Res. 2016;126:8-17.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: